Juliana M. Reed Named Executive Director of the Biosimilars Forum
Reed to head the leading voice for the biosimilars industry
The Biosimilars Forum Board of Directors has appointed Juliana M. Reed as its executive director. Reed has served as the Biosimilars Forum president for more than eight years and was one of its original co-founders. She brings more than 30 years of experience in the healthcare sector to the Forum and has served in executive roles leading global corporate and government affairs for Pfizer, Hospira and Coherus BioSciences.
As the Biosimilars Forum president, Reed oversaw advocacy and awareness campaigns to advance biosimilar access and adoption in the United States.
“I am extremely excited to lead the most influential organization for the biosimilars industry at such a critical time,” said Reed. “My top priority will be to work with our members, Congress and the FDA as a voice for our industry and patients. I will advocate for commonsense policy solutions that give more patients access to life-saving, lower-cost biosimilars.”
This announcement highlights the Forum’s commitment to education around the efficacy, safety and cost-saving potential of biosimilars, as well as the Forum’s efforts to ensure access to these critical medications for all who need them.
“Juliana understands that biosimilars play a critical role in lowering drug prices for all Americans,” said Tiffany Fletcher, vice president of the Biosimilars Forum and Head of Global Access Policy at Viatris. “Juliana is the ideal leader for the Biosimilars Forum, and she will help stakeholders across the healthcare spectrum understand the importance of timely access to biosimilars.”
A biosimilar is an FDA-approved biologic product that is approved based on the demonstration of a high degree of similarity to an FDA‐approved reference biologic product; biosimilars must also show no clinically meaningful difference to the reference product in terms of safety and effectiveness. Biosimilars are used to treat many conditions, including cancer, diabetes, Crohn’s disease, arthritis, macular degeneration, macular edema, and myopic choroidal neovascularization.
The Biosimilars Forum is a nonprofit organization working to advance biosimilars in the United States with the goals of expanding access and availability and improving healthcare outcomes. Since its inception, the Forum has worked to expand the uptake of biosimilars throughout the healthcare system through policies that will increase access for patients and lower costs through increased competition. Forum members represent companies with the most significant U.S. biosimilars development portfolios.
For more information on how the Biosimilars Forum is advocating for patients across the country, visit our website: biosimilarsforum.org.